LOS ANGELES, Feb. 28, 2018 -- Strategic Directions International (SDi), a division of BioInformatics Inc., today announced the release of the SDi Global Assessment Report 2018: The Laboratory Analytical & Life Science Instrumentation Industry. The 800+ page report details updated size, growth and market analyses for over 50 instruments in six major technology categories. In addition the projections, based on 15 editions over 20+ years of publication, are made on the industry’s prospects out to 2022 and include technology overviews, and detail market segment and regional developments. For this first time, users of the report will have an option to receive an electronic data stream updating the market projections on a quarterly basis.
“The overall analytical instrument industry is expected to grow by 4.6% reaching $71 billion by 2022,” said Mike Tice, Senior Vice President, Business Intelligence at SDi. “As the technology often on the leading edge of scientific research capabilities, mass spectrometry continues to have a bright future as the fastest-growing instrument segment and we project it will grow by almost 7%. Surface science techniques are also poised to make great gains buoyed by growing opportunities in life science applications.”
The SDi Global Assessment Report 2018: The Laboratory Analytical & Life Science Instrumentation Industry is the most trusted “gold standard” for measuring the size and growth of the analytical and life science instrumentation industry globally. A complimentary Executive Summary can be downloaded here. More information on the Global Datastream, which includes both the Global Assessment Report, and quarterly updates, can be found here. Additionally, users will receive the report in a PDF as well as an editable PowerPoint format.
The report covers 82 individual instrumentation and related technologies. Each technology is segmented according to several primary classifications typically related to underlying techniques. The six major sections updated this year include chromatography, life science instrumentation, mass spectrometry, molecular spectroscopy, atomic spectroscopy, and lab equipment. The remaining sections are updated every two years, and the surface science, materials characterization, lab automation, and general analytical techniques categories will contain an updated and extensive technology overview.
For each instrument and category, the report quantifies the regional distribution of demand; the size of the market segmented according to initial systems, aftermarket, and service; unit shipments/installations; growth rates; and demand by industry and lab function. Each section also explores the current state of the competitive playing field, including a list of the top vendors’ market shares, a vendor participation matrix, recent developments, and concludes with a short discussion that suggests where the market might be headed over the next five years from the related standpoints of technology, competition, and growth.
About SDi, BioInformatics Inc, and Instrument Business Outlook
Strategic Directions International (SDi), a leading international management-consulting firm in the highly specialized field of analytical instruments, was acquired by BioInformatics Inc in 2014. The two firms combined to form the premier research and advisory firm serving the life science and analytical instrument industry. By leveraging our verified online professional network of tens of thousands of scientists in The Science Advisory Board®, we have supported more than 500 companies and provided insights that lead to better business decisions. Our expertise includes assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customers’ brand loyalty, and evaluating brand strength and positioning, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning. SDi and BioInformatics Inc are supported by their own bi-weekly online publication Instrument Business Outlook.
www.gene2drug.com
For more information contact: Mike Tice Senior Vice President of Business Intelligence Strategic Directions International A division of BioInformatics Inc. 6242 Westchester Parkway, Suite 100 Los Angeles, CA 90045-4820 United States Phone: 310.641.4982 [email protected]


American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Washington Post Publisher Will Lewis Steps Down After Layoffs
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 



